Michael D Keller
Overview
Explore the profile of Michael D Keller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kinoshita H, Walti C, Webber K, Pezzella G, Jensen-Wachspress M, Lang H, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40032074
Chimeric antigen receptor-modified T (CAR-T) cell therapies are gaining wider use in relapsed and refractory malignancies. However, data on vaccination in this population is lacking. We evaluated T cell responses...
2.
Bosticardo M, Dobbs K, Delmonte O, Martins A, Pala F, Kawai T, et al.
Sci Immunol
. 2025 Jan;
10(103):eadq1697.
PMID: 39792639
Human recombination-activating gene (RAG) deficiency can manifest with distinct clinical and immunological phenotypes. By applying a multiomics approach to a large group of -mutated patients, we aimed at characterizing the...
3.
Duran J, Sayed S, Dalalo M, Mauracher A, Knight M, Conrey P, et al.
bioRxiv
. 2024 Dec;
PMID: 39713308
Signal transduction downstream of activating stimuli controls CD8+ T cell biology, however these external inputs can become uncoupled from transcriptional regulation in Primary Immune Regulatory Disorders (PIRDs). Gain-of-function (GOF) variants...
4.
Durkee-Shock J, Cohen A, Maghzian N, Pezzella G, Jensen-Wachspress M, Hostal A, et al.
J Infect Dis
. 2024 Aug;
PMID: 39140311
Background: Chronic norovirus infection (CNI) causes significant morbidity in immunocompromised patients. No effective prevention or treatment currently exists. Methods: Two patients with inborn errors of immunity, X- linked severe combined...
5.
Khoury R, Grimley M, Nelson A, Leemhuis T, Cancelas J, Cook E, et al.
Am J Transplant
. 2024 Apr;
24(9):1634-1643.
PMID: 38643944
Reactivation or primary infection with double-stranded DNA viruses is common in recipients of solid organ transplants (SOTs) and is associated with significant morbidity and mortality. Treatment with conventional antiviral medications...
6.
Keller M, Hanley P, Chi Y, Aguayo-Hiraldo P, Dvorak C, Verneris M, et al.
Nat Commun
. 2024 Apr;
15(1):3258.
PMID: 38637498
Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed...
7.
8.
Keller M, Schattgen S, Chandrakasan S, Allen E, Jensen-Wachspress M, Lazarski C, et al.
Nat Commun
. 2024 Mar;
15(1):2749.
PMID: 38553461
Virus-specific T cells (VST) from partially-HLA matched donors have been effective for treatment of refractory viral infections in immunocompromised patients in prior studies with a good safety profile, but rare...
9.
Roth K, Darwish C, Keller M, Hammer B, Ahmed-Winston S, Escalante E, et al.
Pediatr Blood Cancer
. 2024 Jan;
71(4):e30871.
PMID: 38279890
Background: Drug shortages are a common issue that healthcare systems face and can result in adverse health outcomes for patients requiring inferior alternate treatment. The United States recently experienced a...
10.
Le Voyer T, Parent A, Liu X, Cederholm A, Gervais A, Rosain J, et al.
Nature
. 2023 Nov;
623(7988):803-813.
PMID: 37938781
Patients with autoimmune polyendocrinopathy syndrome type 1 (APS-1) caused by autosomal recessive AIRE deficiency produce autoantibodies that neutralize type I interferons (IFNs), conferring a predisposition to life-threatening COVID-19 pneumonia. Here...